This book provides a systematic review of the management and treatment of this disease. The concise and highly structured chapters feature essential background knowledge and commentary on recent advances within each step of a range of patient pathways. Management of Muscle Invasive Bladder Cancer provides a framework for patients’ care based on the research, as well as practically and clinically oriented guidelines. This book is relevant to trainees and practicing urologists and oncologists, in addition to medical professionals involved in the treatment of bladder cancer.
This book presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body.
This book covers the latest advances in non-muscle invasive bladder cancer care.
Risk Management and Treatment of Non-muscle-invasive Bladder Cancer
This book provides an overview of the most hotly debated areas in bladder cancer. Authors have focused on the emerging role of markers for NMI UC and various ways of improving the efficacy of current chemotherapy in the first section.
This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients.
This book covers the application of chemotherapy for muscle invasive and advanced disease. The evidence-based application of multimodality therapy is highlighted.
When are they best used? What is the optimal sequence of treatments for individual patients? This third edition of 'Fast Facts: Bladder Cancer' has been updated extensively throughout by two new authors, bringing a fresh perspective.
Dr. Holzbeierlein has created an issue devoted to the current knowledge and best practice of Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.
This book covers the latest advances in non-muscle invasive bladder cancer care.
This major urologic malignancy was one of the first cancers to be linked to occupational and environmental exposure to carcinogens. Bladder cancer is the 5th most common cancer of American men and the 8th most common c